Clinical trial Recruiting at 2 sites Phase 4 Interventional Ages 2 to 18

Evaluating changes in gut bacteria after enema treatment for constipation in children

Official title: Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen

Run by Indiana University · NCT05821309 · Data updated 2026-11-12

This study is testing how a special enema treatment for constipation affects the gut bacteria in children aged 2 to 18 over several months.

Quick facts

PhasePhase 4
Study typeInterventional
Ages2 Years to 18 Years
SexAll
Enrollment65 (estimated)
SponsorIndiana University
Academic / other
Locations2 sites (Carmel, Indiana and 1 other locations)
StatusRecruiting
StartedJune 8, 2023
Main results expectedJuly 2027
Study endsJuly 2027
Registry record updatedAugust 18, 2026
Trial IDNCT05821309 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 2 to 18 years with chronic functional constipation requiring a MACE procedure and intact colonic motility.

Probably not a fit

Patients with underlying anatomical or pathological causes of constipation or those who have had prior gastrointestinal surgeries may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the changes in the fecal microbiome of pediatric patients suffering from chronic functional constipation before and after the placement of a Malone Antegrade Continence Enema (MACE) and the initiation of a bowel flush regimen. Children aged 2 to 18 years will have their microbiome sequenced through stool samples collected at various intervals: before the procedure and at 1, 4, and 8 months post-treatment. The study will also randomize the bowel flush regimen between two types of PEG solutions to assess their impact on microbiome diversity. The research aims to provide insights into how these interventions affect gut health in constipated children.

Why it matters

Potential benefit: If successful, this study could lead to improved management strategies for chronic constipation in pediatric patients by understanding the role of the microbiome.

How similar studies have gone: While studies on the microbiome and constipation exist, this specific approach combining MACE and microbiome analysis is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Recalcitrant chronic functional constipation necessitating a MACE appendicostomy or cecostomy for treatment at Riley Hospital for Children
* Intact colonic motility as evidenced by CMS studies

Exclusion Criteria

* Underlying anatomic or pathologic etiology for constipation
* History of prior gastrointestinal surgery (excluding placement of G or GJ tubes)
* Underlying severe GI disease unrelated to the patient's chronic constipation
* Use within the past month of consent of probiotic supplements, prebiotic supplements or antibiotics

Where it's running

  • IU North Hospital
    Carmel, Indiana, United States
    Recruiting
  • Riley Hospital for Children
    Indianapolis, Indiana, United States
    Recruiting

Study contacts

  • Principal investigator: Kate Hawa, DO — Riley Hospital for Children
  • Study coordinator: Erik Andrewski, MD
  • Email: edandrew@iupui.edu
  • Phone: 317-944-3774

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.